GLP-1 receptor agonist · FDA-approved · Weekly subcutaneous
Semaglutide: the GLP-1 agonist that reset modern metabolic care.
Semaglutide is a long-acting GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). It slows gastric emptying, blunts appetite, and improves glycemic control — producing 12–17% mean body-weight loss in landmark trials.
Free shipping over $150 · Pay with card or crypto
What Semaglutide is
Semaglutide is a 31-amino-acid analogue of human GLP-1 (glucagon-like peptide-1), modified at positions 8 and 34 and bound to a C18 fatty-acid chain that enables albumin binding and a ~7-day half-life.
It is the active ingredient in Ozempic (weekly injectable, type 2 diabetes), Wegovy (weekly injectable, chronic weight management), and Rybelsus (daily oral tablet, type 2 diabetes) — all from Novo Nordisk.
Compounded semaglutide was widely dispensed during the FDA shortage (2022–2024). With the shortage resolved, U.S. compounding under §503A/503B is now legally restricted; most clinical use should reference branded products.
How it works
GLP-1 is an incretin hormone released by intestinal L-cells after meals. It potentiates glucose-dependent insulin release, suppresses glucagon, and signals satiety to the hypothalamus and brainstem.
Semaglutide mimics endogenous GLP-1 but resists degradation by DPP-4, producing tonic GLP-1 receptor activation. This slows gastric emptying (early satiety, smaller meals) and acts centrally to reduce food reward and cravings.
Beyond appetite, sustained GLP-1 receptor activity reduces hepatic glucose output, improves beta-cell function, and modestly lowers systolic blood pressure — driving the cardiometabolic benefits seen in SUSTAIN-6 and SELECT.
What patients use it for
Significant, durable weight loss
STEP-1 demonstrated mean 14.9% body-weight reduction at 68 weeks at 2.4 mg weekly versus 2.4% placebo. STEP-5 confirmed durability through 104 weeks.
Glycemic control in type 2 diabetes
SUSTAIN trials show HbA1c reductions of 1.5–1.8% with weekly semaglutide — among the largest of any non-insulin diabetes drug.
Cardiovascular risk reduction
SELECT (2023, N=17,604) reported a 20% reduction in major adverse cardiovascular events in adults with overweight/obesity and established CVD — no diabetes required.
Improvement in NASH and sleep apnea
Phase 2 NASH data and Phase 3 OSA data (SURMOUNT-OSA analogue programs) show meaningful improvement in hepatic and respiratory endpoints linked to obesity.
Evidence summary
STEP program (Wegovy): six Phase 3 RCTs (N>4,500) in adults with obesity, showing 12–17% mean weight loss across populations including type 2 diabetes (STEP-2) and adolescents (STEP-TEENS).
SUSTAIN program (Ozempic): ten Phase 3 RCTs in type 2 diabetes, plus SUSTAIN-6 cardiovascular outcomes trial showing a 26% reduction in MACE in high-CV-risk T2D.
SELECT (Lincoff AM et al., NEJM 2023): the first cardiovascular outcomes trial of a GLP-1 in non-diabetic overweight/obesity — a regulatory and clinical landmark.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
Wegovy titration: 0.25 mg weekly × 4 weeks → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg weekly maintenance. Slow titration meaningfully reduces GI side effects.
Ozempic titration: 0.25 mg → 0.5 mg → 1.0 mg → 2.0 mg weekly. Maintenance is individualized by glycemic and tolerability response.
Injection sites: abdomen, thigh, or upper arm. Site rotation reduces injection-site reactions. Missed-dose rules differ by product label — confirm with your prescriber.
Safety and contraindications
Most common side effects are gastrointestinal: nausea (~44%), diarrhea, constipation, vomiting. Most are titration-dependent and improve over the first 8–12 weeks.
Boxed warning: risk of medullary thyroid carcinoma in rodents — contraindicated in personal or family history of medullary thyroid carcinoma or MEN-2.
Other warnings: pancreatitis, gallbladder disease (especially with rapid weight loss), diabetic retinopathy progression in T2D, acute kidney injury from volume depletion.
Not recommended in pregnancy or breastfeeding. Discontinue at least 2 months before a planned pregnancy.
Who it's typically considered for
- Adults with BMI ≥30, or ≥27 with a weight-related comorbidity (per Wegovy label)
- Adults with type 2 diabetes seeking improved glycemic control with weight benefit
- Patients with overweight/obesity and established cardiovascular disease (per SELECT)
- Patients who can tolerate weekly injection and slow titration
Frequently asked questions
How fast does semaglutide work for weight loss?
Appetite and food-noise reduction often begin within 1–2 weeks. Measurable weight loss typically starts in weeks 4–8; full effect emerges over 6–12 months of titrated therapy.
Is compounded semaglutide still legal?
The FDA declared the semaglutide shortage resolved in 2025. Outside narrow individualized clinical exceptions, broad commercial compounding of semaglutide is no longer permitted. Most U.S. patients should use branded Ozempic, Wegovy, or Rybelsus.
What happens if I stop semaglutide?
STEP-1 extension data showed ~two-thirds of weight loss is regained within one year of discontinuation. Obesity is a chronic disease; maintenance dosing or a transition plan is typically required.
Semaglutide vs tirzepatide — which is more effective?
Tirzepatide (SURMOUNT-1: ~20.9% weight loss) outperformed semaglutide (STEP-1: ~14.9%) on weight endpoints in indirect and direct comparisons (SURMOUNT-5). Tolerability is comparable.
Do I need to follow a special diet?
No specific diet is required, but a protein-forward, lower-glycemic eating pattern preserves lean mass and reduces nausea. Resistance training during the titration phase protects skeletal muscle.
Will it affect my mental health?
Large RCTs and pharmacovigilance reviews (FDA, EMA) have not confirmed a causal link to suicidal ideation. Patients with active eating-disorder pathology or severe depression should be screened by their clinician.
Can I drink alcohol on semaglutide?
Moderate alcohol is not contraindicated but is often less appealing on therapy. Heavy use raises pancreatitis and hypoglycemia risk (especially in T2D on insulin/sulfonylurea).
Is semaglutide safe long-term?
Cumulative trial exposure now exceeds 5 years (SUSTAIN-6, SELECT). Safety profile is consistent with shorter studies. Indefinite use is reasonable when clinically indicated.
Sources
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM (2021). — pubmed.ncbi.nlm.nih.gov/33567185
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM (2023). — pubmed.ncbi.nlm.nih.gov/37952131
- Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). NEJM (2016). — pubmed.ncbi.nlm.nih.gov/27633186
- FDA prescribing information — Wegovy (semaglutide injection 2.4 mg). — www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf
Considering Semaglutide?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Related peptides
Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
NPI 1609792902 · Last reviewed: July 3, 2026
Last reviewed July 3, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.